Publicacións en colaboración con investigadores/as de Hospital Universitario La Paz (14)

2025

  1. The CNIC polypill (Acetylsalicylic acid + Atorvastatin + Rampril) in secondary prevention of cardiovascular disease in patients with type 2 diabetes: A comparative analysis with alternative therapeutic approaches

    International Journal of Cardiology, Vol. 418

2024

  1. Lipoprotein(a) and Long-Term Recurrent Infarction After an Acute Myocardial Infarction

    American Journal of Cardiology, Vol. 211, pp. 9-16

  2. Patients who suffer a first atherosclerotic cardiovascular event while taking statins are often far off of lipid targets

    Nutrition, Metabolism and Cardiovascular Diseases, Vol. 34, Núm. 1, pp. 90-97

  3. Practical use of new therapies for the management of dyslipidaemias. Consensus SEC/SEA/SEEN/SEMFYC/SEMERGEN/SEMG/SEN/SEACV/S.E.N.

    REC: CardioClinics, Vol. 59, Núm. 4, pp. 310-321

  4. The CNIC-polypill (acetylsalicylic acid, atorvastatin, and ramipril), an effective and cost-saving secondary prevention strategy compared with other therapeutic options in patients with ischaemic heart disease

    European Heart Journal Open, Vol. 4, Núm. 2

2023

  1. Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial

    International Journal of Cardiology, Vol. 391

  2. Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study

    ClinicoEconomics and Outcomes Research, Vol. 15, pp. 559-571

2022

  1. Clinical and therapeutic characterization of the ischemic cardiopathy in Spain. Importance of cardiac rehabilitation programs

    Medicina Clinica Practica, Vol. 5, Núm. 3

  2. The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study

    International Journal of Cardiology, Vol. 361, pp. 116-123

2021

  1. Lipid lowering treatment in patients with very high risk cardiovascular disease. Spanish Society of Cardiology Consensus Document for the use of PCSK9 inhibitors in clinical practice

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48

2015

  1. Novedades en cardiología: Riesgo vascular y rehabilitación cardiaca

    Revista Espanola de Cardiologia, Vol. 68, Núm. 2, pp. 136-143

2014

  1. Temas de actualidad en cardiología: riesgo vascular y rehabilitación cardiaca

    Revista Espanola de Cardiologia, Vol. 67, Núm. 3, pp. 203-210

2013

  1. Temas de actualidad en cardiología: riesgo vascular y rehabilitación cardiaca

    Revista Espanola de Cardiologia, Vol. 66, Núm. 2, pp. 124-130

2009

  1. Prognostic value of low ankle-brachial index in patients with hypertension and acute coronary syndromes

    Journal of Hypertension, Vol. 27, Núm. 2, pp. 341-347